Clinical Trials Sponsored by Astellas Pharma China, Inc

Total 1222 results

Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (LEOPARD)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients (MITRA)

Liver Transplantation | Kidney Transplantation

France, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation (OPTION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) (PROFILE)

Inflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)

Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma Europe Ltd.

Terminated

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease (EFFECT)

Metastatic Prostate Cancer

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics (VEST)

Urinary Bladder, Overactive

Czech Republic
Astellas Pharma Europe B.V.

Completed

Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia (NORMA)

Chronic Lymphocytic Leukemia

Russian Federation
Astellas Pharma Europe B.V.

Completed

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Russian Federation
Astellas Pharma Europe B.V.

Completed

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes (RUBY-1)

Acute Coronary Syndrome

Poland, Colombia, Germany, Korea, Republic of, South Africa, Czech Republic, Netherlands, Hungary, Russian Federation, Mexico, Romania, Argentina, Ukraine, Denmark, Slovakia, Belgium, India, Brazil, Australia, Canada, France
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178

Healthy

France
Astellas Pharma Europe B.V.

Terminated

A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP7657 | Pharmacodynamics of ASP7657

United Kingdom
Astellas Pharma Europe B.V.

Withdrawn

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects

Healthy Volunteers | Pharmacokinetics of ASP3700
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects

Healthy Volunteers | Pharmacokinetics of ASP3700

United Kingdom
Astellas Pharma Europe Ltd.

Terminated

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

Overactive Bladder | Healthy Subjects

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652

Healthy Subjects | Pharmacokinetics of ASP3652 | Pharmacodynamics of ASP3652

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation. (SENIOR)

Kidney Transplantation

Belgium, France, Germany, Spain, Switzerland, United Kingdom, Netherlands
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Irritable Bowel Syndrome

Poland, Germany, Bulgaria, Ukraine, Estonia, Russian Federation, Czech Republic, Lithuania
Astellas Pharma Europe B.V.

Completed

Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Effect of Race

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Japanese | Caucasian

Germany
Astellas Pharma Europe B.V.

Completed

Drug to Drug Interaction Study With Ipragliflozin and Furosemide

Healthy Subjects | Pharmacokinetics of Ipragliflozin

United Kingdom
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Asthma, Bronchial | Bronchial Asthma

Russian Federation, Poland, Germany, Ukraine, Czech Republic
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Asthma, Bronchial | Bronchial Asthma

Russian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
Astellas Pharma Inc

Recruiting

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Solid Tumor

United States
Astellas Pharma Inc

Recruiting

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause (Starlight 3)

Hot Flashes

Japan
Astellas Pharma Inc

Active, not recruiting

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Acute Myeloid Leukemia | FLT3-mutated Acute Myeloid Leukemia

Japan, Korea, Republic of, Taiwan
Astellas Pharma Inc

Active, not recruiting

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Progressive Metastatic Prostate Cancer

China, Hong Kong, Korea, Republic of, Taiwan
Astellas Pharma Inc

Completed

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Metastatic Castration Resistant Prostate Cancer

India
Astellas Pharma Inc

Completed

A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause (Starlight)

Hot Flashes

Japan
Astellas Pharma Inc

Completed

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

De Novo Kidney Transplant Patients

China
Astellas Pharma Inc

Completed

A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia

Benign Prostate Hyperplasia

Japan
Astellas Pharma Inc

Completed

A Study to Assess Effect of Exercise Program Provided by Smartphone Application on the Body Composition

Healthy Volunteers

Japan
Astellas Pharma Inc

Completed

ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-

Anemia in Chronic Kidney Disease Patients Not on Dialysis

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment

Rheumatoid Arthritis

Japan
Astellas Pharma Inc

Completed

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

Depression | Bipolar Disorder

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations (TRUST)

Lupus Nephritis

Japan
Astellas Pharma Inc

Completed

ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis

Anemia | Hemodialysis | Renal Impairment

Japan
Astellas Pharma Inc

Completed

Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers

Healthy Volunteer | Pharmacokinetics of ASP015K

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

Development of Visual Function Evaluation Method (2)

Retinitis Pigmentosa

Japan
Astellas Pharma Inc

Completed

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, India, Philippines, Colombia, Mexico
Astellas Pharma Inc

Completed

A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients

Type 2 Diabetes Mellitus

Japan

3

Subscribe